2 Some of these platforms, however, have not been widely used previously. 1 The most significant difference in developing a COVID‐19 vaccine is the wide range of technology platforms used. The development of the vaccines starts as soon as the virus genome was published in early January.
The most promising solution remains to be an efficient vaccine. The secondary wave of the pandemic was just about to left. To date, the COVID‐19 has infected over one million people worldwide, and more than two million deaths were reported.
Severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) emerged in December 2019 and caused the coronavirus disease 2019 (COVID‐19), which is now pandemic. The observation of the long‐time effect is still needed. The current evidence indicated a minor risk of the acute neurological disorders after the application. We exemplify potential neurological problems these vaccines could cause by looking at previous studies. We reviewed the most promising COVID‐2 vaccines with a particular interest in mechanism(s) and adverse effect(s). It becomes critical to know whether these vaccines will cause neurologic disorders like previously recognized vaccine‐related demyelinating diseases, fever‐induced seizure, and other possible deficits. The reported severe adverse effects raised the worries about their safety. These comprise inactivated vaccines, viral vector vaccine, nucleic acid vaccine, and the protein subunit vaccine platform, which are now quite advanced in trials in various geographic and ethnic populations. Eleven candidates are in advance development. Nucleic acid vaccine uses next‐generation platforms for their development. Classic platforms are used to develop vaccines including live‐attenuated vaccine, inactivated vaccine, protein subunit vaccine, and viral vector. The most efficient solution to end this pandemic is a safe and efficient vaccine. The coronavirus disease 2019 caused by the severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) has become a pandemic with people infected in almost all countries.
0 kommentar(er)
